International edition Finance & trade

Monday, 5 October 2026

National Trade News

Independent coverage of global markets, trade and finance

Finance & markets

Inventiva Eyes Q4 2026 Phase III MASH Data as Lanifibranor Nears Key Test

Policy desk, National Trade News (2026-10-04): Inventiva Eyes Q4 2026 Phase III MASH Data as Lanifibranor Nears Key Test Inventiva (NASDAQ:IVA) said it expects to report top-line results in the fourth… Primary source: original at Nasdaq (nasdaq.com).

· Nasdaq

Inventiva Eyes Q4 2026 Phase III MASH Data as Lanifibranor Nears Key Test

Inventiva (NASDAQ:IVA) said it expects to report top-line results in the fourth quarter of 2026 from its fully enrolled Phase III NATiV3 trial of lanifibranor in patients with metabolic dysfunction-associated steatohepatitis, or MASH.

Chief Executive Officer Andrew Obenshain sai

Read at source

Read also